Study | Populations | Intervention (s) | Comparator (s) | Outcome measures | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Author | Design | N total (IG/CG) | Mean age | H&Y score | UPDRS III score | Disease duration (yr) | Stimulation protocols | Additional therapies | Stimulation protocols or/and additional therapy | Parameters/scales/tools |
Benninger et al., 2010 [45] | RCT | 25 (13/12) | 63.6 ± 9.0 (IG) 64.2 ± 8.8 (CG) | 2.5 ± 0.1 (IG) 2.4 ± 0.2 (CG) | 22.2 ± 8.7 (IG) 17.5 ± 8 (CG) | 10.6 ± 7.1 (IG) 9.1 ± 3.3 (CG) | atDCS (C3, Fp), 2 mA, 20 min, 8 sessions | None | sham tDCS (forehead), 1 mA, 1–2 min, 8 sessions | Walking time |
Beretta et al., 2020 [46] | Crossover RCT | 24 | 68.91 ± 8.47 | NR | 36 ± 14.32 | 4.84 ± 3.11 | atDCS (C3, C4), 2 mA, 20 min, 1 session | None | Sham tDCS (forehead), 2 mA, 30 s-10 s-30 s, 1 session | Peak of CoP velocity |
Bueno et al., 2019 [47] | Crossover RCT | 20 | 64.45 ± 8.9 | 2.25 ± 0.63 | 22.35 ± 6.77 | 7.80 ± 5.32 | atDCS (F3), 2 mA, 20 min, 1 session | None | Sham tDCS (F3), 2 mA, 30 s, 1 session | Gait speed, cadence, numb of step, TUG |
Criminger et al., 2018 a [42] | Crossover RCT | 6 | 68.13 ± 9.76 | NR | 23.44 ± 9.73 | NR | atDCS (F3), 2 mA, 20 min, 1 session | None | Sham tDCS (F3), 1 mA, 30 s × 2, 1 session | TUG |
Dagan et al., 2018a [43] | Crossover RCT | 9 | 68.8 ± 6.8 | 2.5 ± 0.6 | 39.7 ± 14.6 | 9.0 ± 5.7 | atDCS (Cz), 1.5 mA, 20 min, 1 session | None | Sham tDCS (Cz, FC1), 0.5 mA, 20 min, 1 session | FOG provoking test, TUG |
Dagan et al., 2018b [43] | Crossover RCT | 9 | 68.8 ± 6.8 | 2.5 ± 0.6 | 39.7 ± 14.6 | 9.0 ± 5.7 | atDCS (Cz, F3), 1.5 mA, 20 min, 1 session | None | Sham tDCS (Cz, FC1), 0.5 mA, 20 min, 1 session | FOG provoking test, TUG |
Kaski et al., 2014a [41] | Crossover RCT | 8 | NR | NR | NR | NR | atDCS (Cz), 2 mA, 15 min, 1 session | None | Sham tDCS (Cz), 2 mA, 15 min, 1 session | TUG, 6MWT, gait velocity, stride length |
Lattari et al., 2017 [48] | Crossover RCT | 17 | 69.18 ± 9.98 | 2.35 ± 1.06 | 18.0 ± 8.96 | 7.06 ± 2.7 | atDCS (F3/F4), 2 mA, 20 min, 1 session | None | Sham tDCS (F3/F4), 2 mA, 30 s, 1 session | TUG, BBS, DGI |
Manenti et al., 2014 [49] | Crossover RCT | 10 | 67.1 ± 7.2 | 1.3 ± 1.1 | 13.3 ± 5.7 | 8.1 ± 3.5 | atDCS (F3/F4), 2 mA, 7 min, 1 session | None | Sham tDCS (F3/F4), 2 mA, 10 s × 2, 1 session | TUG |
Manor et al., 2021 [50] | RCT | 71 (35/36) | 71 ± 8 (IG) 69 ± 7 (CG) | NR | 40 ± 14 (IG) 37 ± 17 (CG) | 10 ± 6 (IG) 8 ± 6 (CG) | atDCS (F3, Cz), 1.5 mA, 20 min, 10 sessions | None | Sham tDCS, 1.5 mA, 59 s × 2, 10 sessions | TUG, FOG provoking test |
Mishra et al., 2021 [51] | Crossover RCT | 20 | 67.8 ± 8.3 | 1.9 ± 0.9 | NR | 4.8 ± 3.6 | atDCS (F3), 2 mA, 30 min, 1 session | None | Sham tDCS, 2 mA, 30 s, 1 session | Gait speed |
Silva et al., 2018 [52] | RCT | 21 (11/10) | 66 ± 5 (IG) 66 ± 10 (CG) | NR | 35.5 (IG) 29.0 (CG) (median) | 6 ± 6 (IG) 5 ± 1 (CG) | atDCS (Cz, Fcz), 2 mA, 15 min, 1 session | None | Sham tDCS (Cz, Fcz), 2 mA, 10 s-30 s-10 s, 1 session | Stride length, cadence, gait duration, gait speed |
Swank et al., 2016 [53] | Crossover RCT | 10 | 68.7 ± 10.2 | 2 (median) | 24.3 | 7.9 ± 7.1 | atDCS (F3), 2 mA, 20 min, 1 session | None | Sham tDCS (F3), 2 mA, 30 s, 1 session | TUG |
Valentino et al., 2014 [54] | Crossover RCT | 10 | 72.3 ± 3.6 | 2.8 ± 0.5 | 32 ± 10.3 | 11 ± 4.9 | atDCS (Cz), 2 mA, 20 min, 1 session | None | Sham tDCS (Cz), 2 mA, 30 s × 2, 1 session | Stand walk sit test, FOG-Q, num of FOG, duration of FOG, num of steps |
Wong et al., 2022a [44] | RCT | 12 (9/3) | 54.20 ± 4.1 (IG) 58.30 ± 8.0 (CG) | 1.89 ± 0.6 (IG) 1.78 ± 0.7 (CG) | 33.22 ± 13.1 (IG) 23.44 ± 14.7 (CG) | 93.54 ± 68.2 (IG) 100.18 ± 147.0 (CG) (month) | atDCS (C3), 2 mA, 20 min, 1 session | None | Sham tDCS (C3), 2 mA, 30 s & 60 s, 1 session | Speed, cadence, stride time, stride length, TUG |
Wong et al., 2022b [44] | RCT | 12 (9/3) | 50.09 ± 2.4 (IG) 58.30 ± 8.0 (CG) | 1.67 ± 0.5 (IG) 1.78 ± 0.7 (CG) | 25.56 ± 17.0 (IG) 23.44 ± 14.7 (CG) | 73.81 ± 39.2 (IG) 100.18 ± 147.0 (CG) (month) | atDCS (F3), 2 mA, 20 min, 1 session | None | Sham tDCS (C3), 2 mA, 30 s & 60 s, 1 session | Speed, cadence, stride time, stride length, TUG |
Wong et al., 2022c [44] | RCT | 12 (9/3) | 61.30 ± 7.9 (IG) 58.30 ± 8.0 (CG) | 2.13 ± 0.6 (IG) 1.78 ± 0.7 (CG) | 24.22 ± 9.9 (IG) 23.44 ± 14.7 (CG) | 93.54 ± 68.2 (IG) 100.18 ± 147 (CG) (month) | atDCS (O3/O4), 2 mA, 20 min, 1 session | None | Sham tDCS (C3), 2 mA, 30 s & 60 s, 1 session | Speed, cadence, stride time, stride length, TUG |
Chang et al., 2017 [61] | RCT | 32 (16/16) | 63.6 ± 7.5 (IG) 63.8 ± 8.3 (CG) | NR | NR | 4.3 ± 2.5 | atDCS (F3), 1 mA, 20 min, 5 sessions | rTMS (simultaneously), 10 Hz, 20 min, 5 sessions | Sham tDCS (F3) + rTMS (10 Hz, 20 min), 5 sessions | FOG-Q, TUG |
Conceição et al., 2021 [63] | Crossover RCT | 24 | 70.80 ± 7.87 | NR | 36.84 ± 14.31 | 4.3 ± 2.5 | atDCS (F3/F4), 2 mA, 20 min, 1 session (after aerobic exercise 10 min) | Aerobic exercise, 30 min, 1 session | Sham tDCS (F3/F4, 2 mA, 30 s, 10 s, 30 s) + aerobic exercise (30 min), 1 session | Swing time variability, step time variability |
Costa-Ribeiro et al., 2017 [55] | RCT | 22 (11/11) | 61.1 ± 9.1 (IG) 62.0 ± 16.7 (CG) | 1–4 | 19.0 (IG) 19.1 (CG) | 9.8 ± 4.7 (IG) 9.1 ± 5.3 (CG) | atDCS (Cz), 2 mA, 13 min, 10 sessions (before gait training) | Gait training, 30 min, 10 sessions | Sham tDCS (Cz) + gait training, 43 min, 10 sessions | TUG, BBS, cadence, 10MWT, stride length |
Criminger et al., 2018b [42] | Crossover RCT | 6 | 68.13 ± 9.76 | NR | 23.44 ± 9.73 | 6.1 ± 3.8 (IG) 6.28 ± 3.74 (CG) | tDCS during bike (F3), 2 mA, 20 min, 1 session | Bike (stationary bicycle), 20 min, 1 session | Sham tDCS (F3, 1 mA, 30 s × 2) + bike (20 min), 1 session | TUG |
Criminger et al., 2018c [42] | Crossover RCT | 6 | 68.13 ± 9.76 | NR | 23.44 ± 9.73 | 6.1 ± 3.8 (IG) 6.3 ± 3.7 (CG) | atDCS during Wii (F3), 2 mA, 20 min, 1 session | Wii game, 20 min, 1 session | Sham tDCS (F3, 1 mA, 30 s × 2) + Wii game (20 min), 1 session | TUG |
Kaski et al., 2014b [41] | Crossover RCT | 8 | NR | NR | NR | NR | atDCS (Cz), 2 mA, 15 min, 1 session | gait training, 15 min, 1 session | sham tDCS (Cz) + physical training, 15 min, 1 session | TUG, 6MWT, gait velocity, stride length |
Lee et al., 2021 [65] | RCT | 30 (15/15) | 70 ± 3.76 (IG) 1.33 ± 3.27 (CG) | 2.47 ± 0.52 (IG) 2.8 ± 0.41 (CG) | 34.2 ± 7.82 (IG) 38.67 ± 9.6 (CG) | 7 | atDCS (Fcz), 2 mA, 20 min, 20 sessions | Visual cueing training, 20 min, 20 sessions | sham tDCS (Fcz) + visual cueing training, 20 min, 20 sessions | FGA, FOG-Q, gait parameters |
Manenti et al., 2016 [58] | RCT | 20 (10/10) | 69 ± 9.1 (IG) 69.1 ± 5.6 (CG) | 2.2 ± 0.6 (IG) 2.3 ± 0.4 (CG) | 27.8 ± 13.9 (IG) 27.6 ± 8.9 (CG) | NR | atDCS (F3/F4), 2 mA, 25 min, 10 sessions (during physical therapy) | Physical therapy, 25 min, 10 sessions | Sham tDCS (F3/F4) + physical therapy, 25 min, 10 sessions | TUG, four square step test, standing stork test, sit and reach test |
Mishra et al., 2022 [64] | Crossover RCT | 20 | 67.8 ± 8.3 | 1.9 ± 0.9 | NR | 4.8 ± 3.8 | atDCS (F3), 2 mA, 30 min, 1 session (during TUG single and dual task) | TUG single and dual task, 30 min, 1 session | sham tDCS (F3) + TUG single and dual task | TUG |
Na et al., 2022 [56] | RCT | 23 (11/12) | 63.73 ± 6.57(IG) 65.08 ± 6.46 (CG) | 1 (IG) 2 (CG) (median) | 33.64 ± 16.06 (IG) 34.5 ± 12.67 (CG) | 6.27 ± 1.03 (IG) 7 ± 1.41 (CG) | atDCS (Cz), 2 mA, 20 min, 10 sessions (first 20 min of 30 min training) | Treadmill gait training, 30 min, 10 sessions | Sham tDCS (Cz) + treadmill gait training, 30 min, 10 sessions | TUB, BBS, FOG, 10MWT, DGI, FRT |
Fernández-Lago et al., 2017 [57] | Crossover RCT | 18 | 73.28 | 1.65 | 21.17 | NR | atDCS (C3/C4), 2 mA, 20 min, 1 session (during treadmill walking) | Treadmill training, 20 min, 1 session | Sham tDCS (C3/C4) + treadmill training, 20 min, 1 session | Gait speed, stride length, |
Papen et al., 2014 [62] | Crossover RCT | 10 | 64 ± 10 | NR | 29 ± 2 | 6.17 | atDCS (C3/C4), 1 mA, 10 min, 1 session | rTMS, 1 Hz, 15 min, 1 session (immediately after tDCS) | Sham tDCS (C3/C4, 1 mA, 5 s) + rTMS (1 Hz, 15 min), 1 session | Number of steps, step length, double support, stride length, cadence |
Schabrun et al., 2016 [59] | RCT | 16 (8/8) | 72 ± 4.9 (IG) 63 ± 11.0 (CG) | 2 (median) | 47.7 ± 7.5 (IG) 37.7 ± 9.8 (CG) | 6.17 | atDCS (C3), 2 mA, 20 min, 9 sessions (first 20 min of 60 min training) | Physical therapy, 60 min, 9 sessions | Sham tDCS (C3) + physical therapy, 60 min, 9 sessions | Gait velocity, TUG |
Yotnuengnit et al., 2018 [60] | RCT | 40 (20/20) | 68.2 ± 9.8 (IG) 62.7 ± 8.8 (CG) | 2.5 (median) | 11.94 ± 4.68 (IG) 11.17 ± 3.97 (CG) | NR | atDCS (Cz), 2 mA, 30 min, 6 sessions (during physical therapy) | Physical therapy, 30 min, 6 sessions | Sham tDCS (Cz) + physical therapy, 30 min, 6 sessions | Gait speed, step length, step width, cadence |